Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819052 · ClinicalTrials.gov registry record · Phase 3
Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
NCT00819052 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 445 participants.
The verdict
NCT00819052, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate the efficacy of nevirapine extended release (NVP XR) based regimen for HIV-1 infected patients who were receiving nevirapine immediate release (NVP IR) based regimen for at least 18 prior weeks of therapy.
Interventions
- DRUG Nevirapine XR
- DRUG Nevirapine IR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00819052
The ClinicalTrials.gov registry entry for NCT00819052 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nevirapine XR is the first listed.
NCT00819052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00819052 about?
NCT00819052 is a clinical study titled "Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients". The primary objective of this study is to demonstrate the efficacy of nevirapine extended release (NVP XR) based regimen for HIV-1 infected patients who were receiving nevirapine immediate release (NVP IR) based regimen for at least 18 prior weeks of therapy.
What is the current status of trial NCT00819052?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2008-12. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00819052?
The interventions under investigation include: Nevirapine XR (DRUG), Nevirapine IR (DRUG).
Who is sponsoring clinical trial NCT00819052?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.